Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details the acquisition of Ordinary shares by specific individuals on July 9, 2009, at a price of £10.96 per share. These transactions occurred through the Dividend Reinvestment element of the Company's ShareReward Plan. The specific acquisitions were:
- Mr A P Witty: 26 shares
- Mr J S Heslop: 26 shares
- Mr S M Bicknell: 26 shares
- Mr E J Gray: 26 shares
- Mr S A Hussain: 2 shares
- Mr D Learmouth: 26 shares
- Dr D Pulman: 10 shares
- Mr D S Redfern: 26 shares
- Ms C Thomas: 26 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £10.96 per Ordinary share on July 9, 2009.
- Confirm the total number of shares acquired by the listed directors and managers under the ShareReward Plan.
- Review the terms of the ShareReward Plan entered into on October 5, 2001, to understand the Dividend Reinvestment mechanism.